{
    "nctId": "NCT03619681",
    "briefTitle": "Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer",
    "officialTitle": "A Single Arm, Open Lable, Dose Escalation Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy of KN026 Monotherapy in Patients With HER2-positive Advanced Malignant Breast and Gastric Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Gastric Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 63,
    "primaryOutcomeMeasure": "The proportion of patients experiencing dose limiting toxicities.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female subject \\>= 18 years and =\\<75 years.\n* Histologically or cytologically confirmed, locally advanced unresectable or metastatic breast cancer or gastric cancer.\n* ECOG score 0 or 1.\n* Life expectancy \\>3 months.\n* According to the definition of RECIST1.1, the patient has at least one measurable lesion.\n* Adequate organ function prior to start treatment with KN026.\n* Able to understand, voluntarily participate and willing to sign the ICF.\n* Subjects (women of child-bearing potential and males with fertile female partner) must be willing to use viable contraception method.\n\nExclusion Criteria:\n\n* Accepted any other anti-tumor drug therapies within 4 weeks before fist dose.\n* Accepted radiotherapy within 4 weeks before enrollment(Subjects are eligible, which accepted palliative therapies within 2 weeks before the first dose of KN026 for osseous metastatic and all the AEs recovered).\n* An anthracyclines antibiotic treatment, such as doxorubicin (Adriamycin) was received exceeding 300 mg/m\u00b2 within 90 days before first KN026 dosing, or other equivalent dose antharcyclines.\n* Subjects are eligible with clinically controlled and stable neurologic function \\>= 4 weeks, which is no evidence of CNS disease progression; Subjects with spinal cord compression and cancerous meningitis are not eligible.\n* Pregnant or nursing females\uff1bor intend pregnancy within this study period or within 6 monthes after the end of this study.\n* Has not recovered (ie, \\>Grade 1) from AEs except alopecia and anemia.\n* History of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation.\n* Severe chronic and active infection, need to system antibiosis/antiviral treatment.\n* Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well controlled, and need locally treatment or repeated drainage. -",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}